Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants

References

• Thakur SS. Proteomics and Its Application in Pandemic Diseases. J Proteome Res. 2020;19(11):4215–4218.
   PubMed Web of Science ®Google Scholar
• Krittanawong C, Kumar A, Hahn J. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis. 2020;10(4):479–489.
   PubMed Web of Science ®Google Scholar
• Apicella M, Campopiano MC, Mantuano MCOVID. 19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782–792.
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Thakur SS. ACE2 as potential therapeutic target for pandemic COVID-19. RSC Adv. 2020;10(65):39808–39813.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–1714.
   PubMed Web of Science ®Google Scholar
• https://covid19.who.int/
   Google Scholar
• Shim E. Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea. Int J Environ Res Public Health. 2021;18(14):7578.
   PubMed Web of Science ®Google Scholar
• Kannan SR, Spratt AN, Cohen AR, et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. Journal of Autoimmunity. 2021;124:102715.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Timeline: Vaccines. . Cell. 2020;183(2):552.
   PubMed Web of Science ®Google Scholar
• https://www.cdc.gov/vaccines/basics/test-approve.html
   Google Scholar
• https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained
   Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol.2020;50:101422.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897.
   PubMed Web of Science ®Google Scholar
• Bubar KM, Reinholt K, Kissler SM, et al. 19 vaccine prioritization strategies by age and serostatus. Science 2021;371(6532):916–921.
   PubMed Web of Science ®Google Scholar
• Christie A, Mbaeyi SA, Walensky RP. CDC Interim Recommendations for Fully Vaccinated People: an Important First Step. JAMA J Am Med Assoc. 2021;325::1501–1502.
   PubMed Web of Science ®Google Scholar
• https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021 Mar 8. DOI:https://doi.org/10.1038/s41586-021-03398-2.
   Google Scholar
• Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):6013.
   PubMed Web of Science ®Google Scholar
• Paul P, France AM, Aoki Y, et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020-May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):846–850.
   PubMed Web of Science ®Google Scholar
• Moore JP, Offit PA. Offit PA. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants. JAMA. 2021;325(9):821–822.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424.
   PubMed Web of Science ®Google Scholar
• Burki T. Understanding variants of SARS-CoV-2. Lancet. 2021;397(10273):462.
   PubMed Web of Science ®Google Scholar
• Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis. 2021;21(9):1246–1256.
   PubMed Web of Science ®Google Scholar
• Davies NG, Jarvis CI, Edmunds WJ, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar 15;593(7858):270–274.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Lessells RJ, et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med. 2021;27(3):440–446.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021;592(7854):438–443.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384–2393.e12.
   PubMed Web of Science ®Google Scholar
• Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29(4):508–515.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812–827.e19.
   PubMed Web of Science ®Google Scholar
• Li XN, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021; 10(1):1751–1759.
   PubMed Web of Science ®Google Scholar
• Del Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA 2021 Aug 18;326(11):1001.
   PubMed Web of Science ®Google Scholar
• Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462.
   PubMed Web of Science ®Google Scholar
• Sharif N, Ahmed SN, Opu RR, et al. Impact of meteorological parameters and population density on variants of SARS-CoV-2 and outcome of COVID-19 pandemic in Japan. Epidemiol Infect. 2021;149:e103.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra G, Martínez-Rodríguez D, Villanueva-Micó RJ. Impact of a New SARS-CoV-2 Variant on the Population: a Mathematical Modeling Approach. Mathematical Comput Appl. 2021;26(2):25.
   Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg 3055.
   Web of Science ®Google Scholar
• Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021 Mar 9;372:n579.
   PubMedGoogle Scholar
• Guo X, Chen Z, Xia Y, et al. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2). J Transl Med. 2020 Aug 24;18(1):321.
   PubMed Web of Science ®Google Scholar
• Huang SW, Miller SO, Yen CH, et al. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation. Genes (Basel). 2020;12(1):16.
   Web of Science ®Google Scholar
• https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279–288.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637–646.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021; 21(7):950–961.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3):713–721.e9.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr, Falsey AR. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383(25):2439–2450.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Monin L, Laing AG, Muñoz-Ruiz M. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021 May 5;385(2):187–189.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian ECOVID. 19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586(7830):594–599.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — preliminary Report. N Engl J Med. 2020;383:1920–1931.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020;383(16):1544–1555.
   PubMed Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021;384(1):80–82.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427–2438.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571.
   PubMed Web of Science ®Google Scholar
• Doria-Rose N, Suthar MS, Makowski M. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Apr 6;384(23):2259–2261.
   PubMed Web of Science ®Google Scholar
• Doroftei B, Ciobica A, Ilie O-D, et al. Mini- Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics. 2021;11:579.
   Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME. Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020;14(7):e0008548.
   PubMed Web of Science ®Google Scholar
• Pino M, Abid T, Pereira Ribeiro S, et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021;6(61):eabh3634.
   PubMed Web of Science ®Google Scholar
• Gao T, Ren Y, Li S, et al. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microb Cell Fact. 2021;20(1):95.
   PubMed Web of Science ®Google Scholar
• Zang J, Zhu Y, Zhou Y, et al. Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discov. 2021;7(1):71.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Gao Y, Xiao M, et al. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates. Chem Commun. 2021;57(12):1474–1477.
   PubMed Web of Science ®Google Scholar
• Outlaw VK, Bovier FT, Mears MC, et al. Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. mBio. 2020;11(5):e01935–20.
   PubMed Web of Science ®Google Scholar
• Callaway E. Mix-and-match COVID vaccines trigger potent immune response. Nature. 2021;593(7860):491.
   PubMed Web of Science ®Google Scholar
• Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature. 2021;595(7867):344–345.
   PubMed Web of Science ®Google Scholar
• Kunal S, Sakthivel P, Gupta N, et al. Mix and match COVID-19 vaccines: potential benefit and perspective from India. Postgrad Med J. 2021:2021–140648.
   Web of Science ®Google Scholar
• Deming ME, Lyke KE. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med. 2021 Jul 26;27(9):1510–1511.
   PubMed Web of Science ®Google Scholar
• Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043–2046.
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–121.
   PubMed Web of Science ®Google Scholar
• Luchsinger LL, Hillyer CD, Sills J. Vaccine efficacy probable against COVID-19 variants. Science. 2021;371(6534):1116.
   PubMed Web of Science ®Google Scholar
• Emary KRW, Golubchik T, Aley PK. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351–1362.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1885–1898.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Apr 21;384(23):2187–2201.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 May 5;384(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–141.
   PubMed Web of Science ®Google Scholar
• Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29(4):516–521.e3.
   PubMed Web of Science ®Google Scholar
• Sapkal GN, Yadav PD, Ella R, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2. J Travel Med. 2021;28:taab051.
   PubMed Web of Science ®Google Scholar
• Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis 2021 ciab411 https://doi.org/10.1093/cid/ciab411.
   Web of Science ®Google Scholar
• Pegu A, O’Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021; eabj4176. https://doi.org/10.1126/science.abj4176.
   Google Scholar
• Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280.
   PubMed Web of Science ®Google Scholar
• https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/global-urban-areas.html
   Google Scholar
• Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020;20(5):523–524.
   PubMed Web of Science ®Google Scholar